The surge in longevity funding from tech billionaires stems from their mindset of viewing life as a hackable software problem. Accustomed to immense power and control, they see death as the ultimate challenge to conquer, not just a biological inevitability.
Doubling the human lifespan could have a negative societal impact. Since generational turnover drives change and innovation, allowing an older generation to accumulate and hold power, wealth, and influence for longer periods could lead to profound societal stagnation.
The doubling of average life expectancy in 150 years is due to public health, medicine, and nutrition mitigating early-life deaths. The maximum human lifespan remains stalled around 120 years because we haven't yet made significant progress in slowing the fundamental biological process of aging.
Anti-aging research has two main branches. The common approach is to slow the accumulation of damage. A more revolutionary strategy is cellular rejuvenation, which tries to reprogram cells to a younger state, effectively reversing their biological clock rather than just pausing its progression.
Venki Ramakrishnan critiques the stated mission of longevity company Altos Labs, which aims for people to "die young after a long time." He highlights the paradox: if a person is biologically young and healthy, there is no mechanism for them to suddenly die, suggesting the true goal is radical life extension.
Despite AI's power to predict drug candidates, the transition from digital discovery to real-world treatment is a major hurdle. The complex, slow, and expensive processes of manufacturing, clinical trials, and treating actual patients—the "analog world"—will temper AI's revolutionary impact on medicine.
While physics provides strong quantitative skills, its reductionist mindset is ill-suited for biology. Successful physicist-turned-biologists are those who unlearn their original discipline's approach and adopt a new way of thinking centered on complexity, control experiments, and evolutionary context.